

## Quarterly overview

	2021			2020			2019		
	Jul-Sep	Apr-Jun	Jan-Mar	Oct-Dec	Jul-Sep	Apr-Jun	Jan-Mar	Oct-Dec	Jul-Sep
Net sales, SEK million	111.8	110.7	100.6	92.7	98.8	90.6	118.4	129.3	131.2
Gross profit, SEK million	49.9	46.1	44.7	39.2	45.8	37.0	55.2	57.7	62.3
Gross margin, %	44.7	41.7	44.4	42.3	46.4	40.8	46.6	44.6	47.5
EBITDA, SEK million	18.2	8.0	12.3	3.6	28.9	2.4	20.8	20.3	37.8
EBITDA margin, %	16.3	7.2	12.3	3.9	29.3	2.7	17.5	15.7	28.8
Depreciation and impairment of property, plant and equipment, SEK million	3.6	4.2	4.2	4.2	4.4	4.4	4.5	4.1	4.5
EBITA, SEK million	14.7	3.6	8.1	-0.6	24.5	-1.9	16.2	16.2	33.3
EBITA margin, %	13.1	3.3	8.1	-0.6	24.8	-2.1	13.7	12.5	25.4
Amortization and impairment of intangible assets, SEK million <sup>1</sup>	1.6	1.3	1.3	41.1	1.0	1.0	1.0	1.0	1.0
EBIT, SEK million	13.0	2.3	6.8	-41.6	23.5	-3.0	15.2	15.1	32.3
EBIT margin, %	11.7	2.1	6.8	-44.9	23.7	-3.3	12.9	11.7	24.6
Profit after tax, SEK million <sup>2</sup>	7.1	-1.4	0.3	-32.6	20.2	-43.0	7.4	7.2	20.3
Basic earnings per share, SEK	0.37	-0.07	0.02	-1.68	1.04	-2.21	0.38	0.37	1.04
Diluted earnings per share, SEK	0.36	-0.07	0.02	-1.63	0.99	-2.10	0.36	0.35	0.99
Cash flow from operating activities per share, SEK	0.54	0.42	0.65	1.30	0.92	0.91	0.75	1.02	1.23
Return on equity, %	2.7	-0.5	0.1	-11.2	6.6	-13.2	2.2	2.2	6.4
Net debt/ EBIT (R12)	-0.3	-1.4	0.2	0.8	-0.1	0.2	0.0	0.1	0.4
Equity/assets ratio, %	51	50	54	56	56	53	56	57	56

<sup>1</sup> Write-off of acquired laser technology and related capitalized development expenses amounts to SEK 40.0 million in Q4 2020.

<sup>2</sup> Profit/loss from biosurfit and the impairment of the Group's holding in the associate in Q2 2020 are not included in the Group's operating profit. The impairment loss of SEK 36.6 million is recognized in net financial income together with biosurfit's profit/loss and is therefore only shown in profit after tax in the quarterly overview.